NEW YORK, Sept. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=105020&from=4 CLASS PERIOD: April ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sage Therapeutics investors who were adversely affected by alleged securities fraud between April 12, 2021 and July 23, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sa ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=104508&from=3 CLASS PERIOD: Ap ...

Core Viewpoint - Sage Therapeutics, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the effectiveness and regulatory prospects of its drug candidates [1][4]. Company Overview - Sage Therapeutics is a biopharmaceutical company focused on developing brain health medicines, including zuranolone for postpartum depression and major depressive disorder, dalzanemdor for mild cognitive impairment due to Parkinson's Disease, and SAGE-324 for essential tremor [3]. Allegations of the Lawsuit - The lawsuit alleges that Sage Therapeutics made false statements about the effectiveness of zuranolone, dalzanemdor, and SAGE-324, leading investors to believe these drugs had better clinical and regulatory prospects than they actually did [4]. - Specific claims include that zuranolone was less effective for major depressive disorder than represented, and that the FDA was unlikely to approve its New Drug Application for this indication without further studies [4][5]. - The effectiveness of dalzanemdor for mild cognitive impairment was also overstated, as a Phase 2 study did not meet its primary endpoint, leading to a halt in its development [6]. - Similarly, SAGE-324's Phase 2 study for essential tremor failed to demonstrate significant results, resulting in the decision to cease further development [7][8]. Impact on Stock Price - Following the disclosure of the FDA's decision regarding zuranolone on August 4, 2023, Sage Therapeutics' stock price fell nearly 54% [5]. - The announcement regarding dalzanemdor on April 17, 2024, led to a nearly 20% drop in stock price [6]. - The news about SAGE-324 on July 24, 2024, resulted in a nearly 21% decline in stock price [8]. Legal Process - Investors who purchased Sage Therapeutics securities during the class period have until October 28, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1][9].

LOS ANGELES, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"). If you suffered a loss on your Sage investments or would like to inquire about potentially pursuing c ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=103171&from=3 CLASS PERIOD: Ap ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024. Sage is a biopharmaceutical company that develops and commercializes brain health medicines. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP ...

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sage-therapeutics-loss-submission-form/?id=101225&from=3 CLASS PERIOD: Ap ...

Core Viewpoint - The article discusses a class action lawsuit against Sage Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the effectiveness of its drug candidates and subsequent stock price declines following negative disclosures [1][4][5]. Company Overview - Sage Therapeutics is a biopharmaceutical company focused on developing brain health medicines, including zuranolone for postpartum depression and major depressive disorder, dalzanemdor for mild cognitive impairment due to Parkinson's Disease, and SAGE-324 for essential tremor [3][4]. Allegations of the Lawsuit - The lawsuit claims that Sage Therapeutics and its executives made false statements about the effectiveness of zuranolone, dalzanemdor, and SAGE-324, leading investors to believe these drugs had better clinical and regulatory prospects than they actually did [4][5]. - Specific allegations include: - Zuranolone was less effective for major depressive disorder than claimed, affecting its FDA approval chances [4][5]. - Dalzanemdor did not meet its primary endpoint in a Phase 2 study, leading to a halt in its development [6]. - SAGE-324 failed to demonstrate significant efficacy in treating essential tremor, resulting in the cessation of its clinical development [7][8]. Stock Price Impact - Following the disclosure of the FDA's Complete Response Letter regarding zuranolone, Sage Therapeutics' stock price fell nearly 54% [5]. - The announcement of dalzanemdor's Phase 2 study failure led to a nearly 20% drop in stock price [6]. - The failure of SAGE-324's study resulted in a nearly 21% decline in stock price [8]. Legal Process - Investors who purchased Sage Therapeutics securities during the class period (April 12, 2021, to July 23, 2024) can seek to be appointed as lead plaintiff in the lawsuit, which allows them to represent the interests of all affected investors [1][9].

Core Viewpoint - A class action lawsuit has been initiated against Sage Therapeutics, Inc. for alleged securities fraud, with investors from the Class Period (April 12, 2021, to July 23, 2024) being invited to seek lead plaintiff status [1][2]. Company Background - Sage Therapeutics, based in Cambridge, Massachusetts, focuses on developing new treatments for serious brain disorders [3]. Securities Fraud Claims - The lawsuit alleges that Sage Therapeutics made materially false and misleading statements regarding its business and drug efficacy, including: - SAGE-217 (zuranolone) was less effective for major depressive disorder (MDD) than claimed, leading to doubts about FDA approval for MDD [4]. - SAGE-718 (dalzanemdor) was less effective for mild cognitive impairment (MCI) due to Parkinson's Disease (PD) than represented [4]. - SAGE-324, an investigational drug for essential tremor (ET), was also less effective than claimed [4]. Stock Price Impact - Following the FDA's Complete Response Letter on August 4, 2023, regarding zuranolone's effectiveness for MDD, Sage's stock price dropped by $19.35 (53.6%) to $16.75 [5]. - On April 17, 2024, after announcing disappointing Phase 2 study results for SAGE-718, the stock fell by $3.06 (19.58%) to $12.57 [6]. - After the July 24, 2024 announcement regarding SAGE-324's study results, the stock price decreased by $2.70 (20.64%) to $10.38 [7].